An insight into Science Creates
Founded by exited entrepreneurs, Science Creates is a Deep Tech ecosystem that enables scientists and engineers to turn their groundbreaking discoveries into disruptive businesses that can revolutionise the health of people and the planet.
We support our startup community with specialised lab space, expert training and mentoring, a network of partner organisations, and access to investment opportunities.
Through our independent charity and public events, we inspire the next generation of scientists and entrepreneurs.





Our ethos
We believe the next big breakthroughs will emerge at the intersection of fields like quantum, AI, and biotechnology — and that spinouts are the most powerful way to turn those innovations into global impact.
The first step is empowering those at the forefront of knowledge with the right infrastructure, training, resources and investment.
Science Creates is laying the foundations for bold ideas and innovation to thrive and scale, nationwide.
Designed for flexibility, OMX, our new 30,000 sq ft of lab, office, and meeting space for startups and scaleups is set to open in 2026 in Bristol’s city centre.
We currently welcome applications from service providers working in legal, IT, grants, cloud, bespoke software and marketing.
We invest in Deep Tech at the pre-seed and seed stages — and our endgame is global impact.
.webp)


Our focus
Deep Tech refers to innovations based on major breakthroughs in science and engineering, often built on years of research and proprietary technology to solve global challenges. Unlike regular tech, it focuses on transformative, long-term solutions in fields like AI, quantum, synthetic biology and advanced materials.
Deep Tech has the power to revolutionise industries, create new markets, and improve lives. From AI-driven healthcare to sustainable energy and quantum technologies, it tackles critical global issues.
We specialise in Deep Tech for its potential to drive systemic change and create significant impact, providing patient capital and strategic support to turn groundbreaking ideas into scalable businesses.

Biophoundry is accelerating the next generation of precision antibiotics by harnessing the unique properties of phages. Combining its expertise in synthetic biology, robotics and data science, the team is developing faster, affordable and scalable phage solutions for healthcare diagnostics and therapeutics.

Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

Deep Blue Biotech is creating a new generation of superior green chemicals to accelerate the transition to a net-zero future. Leveraging synthetic biology and artificial intelligence, its novel cyanobacteria technology platform decarbonises key, everyday chemicals. By targeting key industries like pharma, beauty and personal care, Deep Blue Biotech seeks to expand its carbon mitigation potential with its cost-effective alternatives to fossil fuel-derived chemicals.



Available for hire for those working in the innovation sector, our versatile spaces can welcome a variety of events.
